Dishman Carbogen Amcis Limited has released the transcript of its Q1 FY27 earnings conference call held on August 17, 2026. The call, covering results for the quarter ending June 30, 2026, featured discussions on operational updates, financial performance, segment breakdowns, and future strategic plans. Key participants included CEO Stephan Fritschi and CFO Harshil Dalal.
Dishman Carbogen Amcis Q1 FY27 Earnings Conference Call Transcript
Dishman Carbogen Amcis Limited has officially published the transcript from its earnings conference call for the first quarter of the Financial Year 2027 (Q1 FY27), which concluded on June 30, 2026. The call took place on August 17, 2026, providing stakeholders with detailed insights into the company’s performance and strategic direction.
Key Participants and Discussion Points
The conference call featured key leadership from Dishman Carbogen Amcis, including Mr. Stephan Fritschi, CEO of Carbogen Amcis, and Mr. Harshil Dalal, Global Chief Financial Officer. They were joined by other corporate participants, including Mr. Paolo Armanino (Chief Operating Officer, India) and Ms. Angela Ameriks (Chief Commercial Officer). The discussions covered operational updates, financial results, segment performance, and future growth prospects.
Operational and Strategic Highlights
Management highlighted several strategic initiatives, including the SPRINT initiative for acquiring early-phase projects, the continued promotion of packaged drug substance products, and intensified interaction between Dishman Carbogen Amcis and Carbogen Amcis. The company noted an increase in order income and discussed efforts to enhance agility and market presence. New sales leadership hires and the strengthening of the sales force were also emphasized.
Financial Performance Overview
The financial performance for Q1 FY27 indicated a 4% de-growth in revenue, amounting to INR 6,776 million, attributed to a postponed order. EBITDA stood at INR 600 million compared to INR 1,406 million in the prior year’s comparable quarter. The company reported a loss before tax of approximately INR 512 million. The CDMO segment revenue was INR 5,343 million, while the Marketable Molecules segment showed significant growth with revenue at INR 1,432 million.
Future Outlook and Guidance
Looking ahead, Dishman Carbogen Amcis anticipates single-digit growth for revenues in FY27, with EBITDA margins expected to be similar to the previous year, potentially slightly higher. For FY28-29, the company projects substantial growth driven by India operations and the CDMO business in Switzerland and France, expecting at least double-digit growth and EBITDA margins closer to 25-26%.
Debt Management and Fundraising
The company is actively working on refinancing and reducing its debt. Plans include raising funds in foreign currency at the promoter entity level to infuse into the Indian entity and prepay high-cost debt. An approval for raising up to CHF 200 million at a 4% interest rate over a 10-year tenor has been secured. The net debt is projected to be around CHF 140-150 million.
Segment-Specific Developments
Specific segment updates included the successful completion of MFDS Korea and U.S. FDA inspections for the Naroda site. The company also reported progress in tech transfers from Switzerland to India, with one major project approved and initiated, and three others in advanced discussion. The introduction of new sales leadership, including the Chief Commercial Officer, was highlighted as a key move to strengthen business development.
Source: BSE
